TSE:4568

April 27, 2022

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.com

1.

Consolidated Statement of Profit or Loss

P1

2.

Sheet to adjust Operating Profit to Core Operating Profit

P2

3.

Revenue of Global Products

P3

4.

Revenue by Business Units and Products

P5

5.

Consolidated Statement of Financial Position

P8

6.

Consolidated Statement of Cash Flows

P10

7.

Number of Employees

P11

8.

Capital Expenditure, Depreciation and Amortization

P11

9.

Summary of Product Outlines

P11

10.

Other Financial Indicators

P12

11.

Quarterly Data

P13

12.

Historical Data

P18

13.

Major R&D Pipeline (Innovative pharmaceuticals)

P22

1. Consolidated Statement of Profit or Loss

FY2020

FY2021

FY2022

- Recognition of financial income due to decrease in contingent

Financial income/expenses

Share of profit or loss of investments accounted for using the equity method

Profit before tax

Income taxes

Profit for the year

7.9%

75.8

6.4%

67.0

104.6%

-8.9 -11.7%

7.2%

83.0

16.0 +23.9%

Profit attributable to owners of the Company

7.9%

76.0

6.4%

67.0

104.6%

-9.0 -11.8%

7.2%

83.0

16.0 +23.9%

Tax rate

Overseas sales ratio

-2.3% 8.9% 41.7% 46.6%Currency Rate (Average)

Currency Rate (Average)

USD/JPY EUR/JPY

106.06 112.38 130.00

123.70 130.56 140.00

*This report is not subject to audit procedures.

※1 Temporary income and expenses are excluded for cost of sales, SG&A expenses and R&D expenses

※2 See page 2 for the definition of temporary income and expenses and the adjustment of operating profit and core operating profit

2. Sheet to adjust Operating Profit to Core Operating Profit

FY2020 Results

Adjustment

JPY Bn

Operating Profit (full)

gains and losses related to sale of fixed assets

gains and losses related to restructuringgains and losses related to impairment,

gains and losses related to loss compensation, reconciliation

Others

Operating Profit (Core)

Revenue

962.5

962.5

Cost of sales SG&A expenses R&D expenses

338.3

-0.0

-

0.5

-

-

337.8

333.1

0.0

-

0.0

15.0

-0.4

318.5

227.4

-0.1

-

0.0

-

-

227.4

Core Operating Profit

63.8

-0.1

-

0.6

15.0

-0.4

78.9

Major Temporary income and Temporary expenses

Temporary income

(Cost of sales)

(SG&A expenses)

(R&D expenses)

Temporary expenses

(Cost of sales)

(SG&A expenses)

(R&D expenses)

0.1

-

-

-

0.4

0.6

*1 Vaccine business loss compensation (15.0)

0.0 0.0 0.1

0.4

0.0 0.4 0.1

0.0

-

0.6

15.0

-

15.6

0.0

0.5 0.0 0.0

15.0 *1

0.5 15.0 0.0

Operating Profit (full)

63.8

-

-

-

-

-

63.8

FY2021 Results

Adjustment

JPY Bn

Operating Profit (full)

gains and losses related to sale of fixed assets

gains and losses related to restructuringgains and losses related to impairment,

gains and losses related to loss compensation, reconciliation

Others

Operating Profit (Core)

Revenue

1,044.9

1,044.9

Cost of sales SG&A expenses R&D expenses

353.3

0.0

-

5.3

-

-

348.0

358.3

-3.8

0.5

0.0

-

9.5

352.1

260.2

-0.1

1.0

5.2

-

-

254.1

Core Operating Profit

73.0

-3.9

1.6

10.4

-

9.5

90.6

Major Temporary income and Temporary expenses

Temporary income

(Cost of sales)

(SG&A expenses)

(R&D expenses)

Temporary expenses

(Cost of sales)

(SG&A expenses)

(R&D expenses)

3.9

-

-

-

0.0

3.9

*1 Gains related to sale of fixed assets of Osaka logistics center (2.1)

*2 Losses rerated to impairment of Intangible assets of Zelboraf (2.8)

Losses rerated to impairment of Intangible assets of Turalio (2.2)

*3 Losses related to closure of PLX (5.8)

*4 Environmental expenditures related to former Yasugawa plant (9.5)

0.0 3.8 *1 0.1

0.0

0.0 3.8 0.1

0.0

1.6

10.4

-

9.5

21.5

0.0 0.0 0.0

0.5 *3 1.0 *3

5.3 *2 0.0 5.2 *3

9.5 *4

5.3 10.0 6.2

Operating Profit (full)

73.0

-

-

-

-

-

73.0

As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses".

3.

Revenue of Global Products (1)

FY2020

FY2021

FY2022

Results

JPY Bn

Results

(vs. Forecast (%))

YoYYoY (%)

Forecast

YoYYoY (%)

Trastuzumab deruxtecan

anti-cancer agent

(HER2-directed antibody drug conjugate)

43.5

80.8

(105.5%)

37.4

+85.9%

159.9

79.1

+97.8%

Product sales

*Incl. Gross profit share in AstraZeneca territory

Enhertu (JPN)

Enhertu (US)

Enhertu (EU)

30.1 4.4 25.7 0.0

65.4

(106.9%)

  • 35.3 +117.1%

    128.4

    • 63.0 +96.4%

      Enhertu (ASCA: Asia, South and Central America)Upfront payment

      Regulatory milestone paymentUS HER2+ Breast Cancer 3L

      EU HER2+ Breast Cancer 3L

      US HER2+ Gastric Cancer 2L/3L

      - 9.8 3.5 0.9 1.0 1.6

      9.6 45.4 9.0 1.4

      (95.6%)

  • 5.2 +119.5%

    (103.5%)

  • 19.7 +76.4%

(126.8%)

9.0

-

1.4

9.8

(100.0%)

-

- - -

16.0 83.1 23.0 6.3

  • 6.4 +67.4%

  • 37.7 +83.0%

  • 14.0 +154.7%

  • 4.9 +355.8%

9.8

-

-

2.2

(100.0%)

-1.3

-37.2%

20.6

18.3

+824.4%

0.9 0.5 0.8

(100.0%)

-

-

0.9

(100.0%)

  • -0.5 -50.0%

    0.5

    (100.0%)

  • -0.8 -50.0%

0.8

- - -

- - -

US HER2+ Breast Cancer 2L

-

EU HER2+ Breast Cancer 2L

-

US HER2-low Breast Cancer (post chemo)

-

EU HER2+ Gastric Cancer 2L

-

US HER2+ or HER2 Mutant NSCLC 2L Quid related payment*

-

-

- - - - - 3.4

- - - - -

(100.0%)

- - - - - 3.4

- - - - - -

3.4

3.4

2.6

2.6

6.9

6.9

1.2

1.2

4.3

4.3

- - - - -

1.1

-2.3

-66.7%

*Payment which shall be paid by AstraZeneca to Daiichi Sankyo if both parties do not enter into potential licensing opportunity (Granting Daiichi Sankyo rights to develop or commercialize AstraZeneca's proprietary products, programs or technologies)

Datopotamab deruxtecan

anti-cancer agent

(TROP2-directed antibody drug conjugate)

3.9

6.1

(100.0%)

2.1

+53.7%

6.9

0.9

+14.1%

Upfront payment

3.9

6.1

(100.0%)

2.1

+53.7%

6.9

0.9

+14.1%

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Daiichi Sankyo Co. Ltd. published this content on 27 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2022 04:14:04 UTC.